You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-interleukin-5

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clinical Relevance of Small Airways Disease in Severe Asthma

Recruiting
  • Asthma
    • Leeuwarden, Netherlands
      Medical Center Leeuwarden
    Jan 23, 2023

    Non-Eosinophilic Biological Effects of IL-5

    Not yet recruiting
    • Asthma
      • (no location specified)
      Sep 6, 2023

      Asthma Trial in United States (Mepolizumab, Placebo)

      Completed
      Has Results
      • Asthma
      • Mepolizumab
      • Placebo
      • Aurora, Colorado
      • +8 more
      Jun 23, 2022

      Asthma Trial (Mepolizumab Injection [Nucala])

      Completed
      • Asthma
      • Mepolizumab Injection [Nucala]
      • (no location specified)
      May 28, 2020

      Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome Trial in Cincinnati (Mepolizumab)

      Completed
      • Hypereosinophilic Syndromes
      • +3 more
      • Cincinnati, Ohio
        Cincinnati Children's Hospital Medical Center
      Jul 27, 2020

      Kidney Cancer Trial in Tampa (Pembrolizumab, Interleukin-2)

      Active, not recruiting
      Has Results
      • Kidney Cancer
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      Jun 21, 2022

      Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

      Completed
      • Metastatic Pancreatic Adenocarcinoma
      • +3 more
      • Aldesleukin
      • +9 more
      • Detroit, Michigan
        Wayne State University/Karmanos Cancer Institute
      Mar 30, 2022

      Healthy Trial in Qingdao (VDJ001, Placebo)

      Completed
      • Healthy
      • Qingdao, Shandong, China
        the Affliated Hospital of Qingdao University
      Aug 30, 2023

      Idiopathic Multicentric Castleman's Disease Trial in Beijing, Chengdu (Recombinant Humanized Anti-interleukin-6 Receptor

      Recruiting
      • Idiopathic Multicentric Castleman's Disease
      • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg
      • +2 more
      • Beijing, China
      • +2 more
      Apr 26, 2022

      Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)

      Recruiting
      • Solid Tumor
      • TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
      • Aldesleukin
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Jan 31, 2023

      Melanoma Stage III, Melanoma Stage IV, Inoperable Disease Trial in Tampa (Interleukin-2, Ipilimumab, Nivolumab)

      Recruiting
      • Melanoma Stage III
      • +2 more
      • Tampa, Florida
        Moffitt Cancer Center
      Dec 6, 2022

      Inflammatory Response, Cardiac Disease Trial (Colchicine 0.5 MG, Placebo)

      Not yet recruiting
      • Inflammatory Response
      • Cardiac Disease
      • Colchicine 0.5 MG
      • Placebo
      • (no location specified)
      Nov 1, 2023

      Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)

      Active, not recruiting
      • Malignant Neoplasm
      • aldesleukin
      • +7 more
      • Los Angeles, California
        University of California at Los Angeles (UCLA )
      Dec 1, 2022

      Moderate to Severe Active Rheumatoid Arthritis Trial in Beijing (HS628+MTX, Actemra +MTX)

      Completed
      • Moderate to Severe Active Rheumatoid Arthritis
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 14, 2023

      Acute Coronary Syndromes Trial in Cambridge (Interleukin-2 [IL-2], Placebo Dextrose 5% solution)

      Recruiting
      • Acute Coronary Syndromes
      • Interleukin-2 [IL-2]
      • Placebo Dextrose 5% solution
      • Cambridge, Cambridgeshire, United Kingdom
        Addenbrooke's Hospital
      May 31, 2022

      Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck

      Active, not recruiting
      Has Results
      • Metastatic Head and Neck Squamous Cell Carcinoma
      • +2 more
      • Cetuximab
      • +2 more
      • Washington, District of Columbia
      • +1 more
      Mar 25, 2022

      Clinical Characterization and Outcome of Anti-IgLON5 Disease

      Recruiting
      • Anti-IgLON5 Disease
      • Evaluation of clinical and paraclinical data.
      • Bron, France
        Hospices Civils de Lyon
      Nov 9, 2023

      Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

      Recruiting
      • Advanced Clear Cell Renal Cell Carcinoma
      • +3 more
      • Aldesleukin
      • Pembrolizumab
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Oct 5, 2022

      Stroke, Acute, Ischemic Stroke Trial in Jacksonville (Melatonin)

      Not yet recruiting
      • Stroke, Acute
      • Ischemic Stroke
      • Melatonin
      • Jacksonville, Florida
        University of Florida College of Medicine-Jacksonville
      Feb 3, 2022

      Asthma Trial in Canada, United States (Placebo, Benralizumab)

      Completed
      Has Results
      • Asthma
      • Placebo
      • Benralizumab
      • Tampa, Florida
      • +10 more
      Oct 27, 2020

      Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5

      Completed
      • Paroxysmal Nocturnal Hemoglobinuria
      • Anti-C5 antibody treatment
      • Paris, France
        AP-HP Hôpital Saint Louis
      Apr 24, 2023

      Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder Trial in New Haven (Ketamine, Perampanel, Placebo)

      Not yet recruiting
      • Depressive Disorder, Major
      • +2 more
      • New Haven, Connecticut
        Yale University
      Jun 26, 2023

      Pancreaticoduodenectomy, Antibiotherapy Trial (Antibioprophylaxis (Piperacillin-tazobactam), 5 days Antibiotherapy

      Not yet recruiting
      • Pancreaticoduodenectomy
      • Antibiotherapy
      • Antibioprophylaxis (Piperacillin-tazobactam)
      • 5 days Antibiotherapy (Piperacillin-tazobactam)
      • (no location specified)
      Nov 3, 2023

      Tumor Malignant, Tumor, Experimental, Solid Tumor, Adult Trial in Taipei (JS014, Interleukin 21 and humanized anti-human serum

      Active, not recruiting
      • Neoplasm Malignant
      • +3 more
      • JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
      • Pembrolizumab - anti-PD-1 antibody
      • Taipei, Taiwan
        Wanfang Hospital -Taipei Medical University
      Mar 16, 2022

      Triple Negative Breast Cancer Trial in Los Angeles (biological, procedure, drug)

      Not yet recruiting
      • Triple Negative Breast Cancer
      • Aldesleukin
      • +12 more
      • Los Angeles, California
        USC / Norris Comprehensive Cancer Center
      Aug 9, 2023